Prosecution Insights
Last updated: April 19, 2026
Application No. 19/210,825

CDK INHIBITORS

Non-Final OA §DP
Filed
May 16, 2025
Examiner
RODRIGUEZ, RAYNA B
Art Unit
1628
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Genentech Inc.
OA Round
2 (Non-Final)
32%
Grant Probability
At Risk
2-3
OA Rounds
3y 2m
To Grant
55%
With Interview

Examiner Intelligence

Grants only 32% of cases
32%
Career Allow Rate
180 granted / 562 resolved
-28.0% vs TC avg
Strong +23% interview lift
Without
With
+22.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
63 currently pending
Career history
625
Total Applications
across all art units

Statute-Specific Performance

§101
1.7%
-38.3% vs TC avg
§103
45.2%
+5.2% vs TC avg
§102
16.1%
-23.9% vs TC avg
§112
21.9%
-18.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 562 resolved cases

Office Action

§DP
DETAILED ACTION This office action is in response to applicant’s filing dated February 18, 2026. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of Claims Claims 1-11 are pending in the instant application. Election/Restrictions Applicant’s election without traverse of Group I, drawn to a compound represented by the formula of claim 1 as the elected invention and a formulation species with no additional components required, in the reply filed on October 13, 2025 is acknowledged. Claims 3-11 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on August 18, 2025. Claims 1 and 2 are presently under examination. Priority The present application is a CON of US Application No. 18/785,844 filed on July 26, 2024, which is a DIV of US Application No. 17/922,804 filed on November 2, 2022, which is a 371 of PCT/US2021/030728 filed on May 4, 2021, which claims benefit of foreign priority to PCT/CN2020088585 filed on May 5, 2020. Information Disclosure Statement The information disclosure statement (IDS) submitted on February 18, 2026 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner, except where marked with a strikethrough. Objections and/or Rejections and Response to Arguments Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. The following rejections and/or objections are either reiterated (Maintained Objections and/or Rejections) or newly applied (New Objections and/or Rejections, Necessitated by Amendment or New Objections and/or Rejections, NOT Necessitated by Amendment). They constitute the complete set presently being applied to the instant application. New Objections and/or Rejections Not Necessitated by Claim Amendment Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1 and 2 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 2-12 of copending Application No. 18/210,611 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because: The instant claims are directed to a compound having the structural formula: PNG media_image1.png 225 505 media_image1.png Greyscale or a pharmaceutically acceptable salt or a stereoisomer thereof. The copending claims are directed to a compound having the structural formula: PNG media_image2.png 227 441 media_image2.png Greyscale Thus, the copending claims would anticipate the instant claims. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Response to Arguments Since a new rejection was issued (see above), it is the Examiner’s belief that most of the arguments presented by Applicant have been considered/answered in the rejection itself. Conclusion Claims 1 and 2 are rejected. No claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to RAYNA B RODRIGUEZ whose telephone number is (571)272-7088. The examiner can normally be reached 8am-5:00pm, Monday - Thursday. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy L Clark can be reached at 571-272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Rayna Rodriguez/ Primary Examiner, Art Unit 1628
Read full office action

Prosecution Timeline

May 16, 2025
Application Filed
Nov 04, 2025
Non-Final Rejection — §DP
Feb 18, 2026
Response Filed
Mar 18, 2026
Non-Final Rejection — §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12545851
FRAGRANCES WITH NOTE OF LILY OF THE VALLEY
2y 5m to grant Granted Feb 10, 2026
Patent 12534429
Heterodimers of Glutamic Acid
2y 5m to grant Granted Jan 27, 2026
Patent 12528769
SYNTHESIS OF (2S,5R)-5-(2-CHLOROPHENYL)-1-(2'-METHOXY-[1,1'-BIPHENYL]-4- CARBONYL)PYRROLIDINE-2-CARBOXYLIC ACID
2y 5m to grant Granted Jan 20, 2026
Patent 12527767
EYE DROPS TO TREAT CHEMICALLY INDUCED CORNEAL DAMAGE
2y 5m to grant Granted Jan 20, 2026
Patent 12521377
USES OF (+)-B-DIHYDROTETRABENAZINE IN METHODS OF TREATING MOVEMENT DISORDER
2y 5m to grant Granted Jan 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

2-3
Expected OA Rounds
32%
Grant Probability
55%
With Interview (+22.6%)
3y 2m
Median Time to Grant
Moderate
PTA Risk
Based on 562 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month